Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer
Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer
复制标题
DOI：
10.1016/j.canlet.2012.10.006
复制
发表时间：
2013-01-28
期刊：
影响因子：
9.7
通讯作者：
Dong, Xiaoqun
中科院分区：
文献类型：
--
作者：
Chen, Xuesong;Meng, Qingwei;Dong, Xiaoqun
血管紧张素Ⅱ 1型受体（AT 1 R）促进肿瘤的侵袭、迁移、转移和血管生成。我们探讨了AT 1 R拮抗剂在乳腺癌中的潜在抗肿瘤作用。我们发现，血管紧张素II促进细胞增殖和上调血管内皮生长因子A（VEGF-A）在MCF-7细胞的表达。氯沙坦下调血管紧张素II处理的MCF-7细胞中VEGF-A的表达。坎地沙坦可下调MCF-7移植瘤小鼠VEGF-A的表达，抑制肿瘤生长和血管生成。102例乳腺癌患者中AT 1 R和VEGF-A表达与微血管密度增加相关。我们的数据表明，AT 1 R拮抗剂可能是有用的抑制乳腺癌通过抑制血管紧张素II。(C)2012爱思唯尔爱尔兰有限公司保留所有权利。
Angiotensin II type 1 receptor (AT1R) promotes tumor invasion, migration, metastasis and angiogenesis. We explored the potential antitumor effects of AT1R antagonists in breast cancer. We found that angiotensin II promoted cell proliferation and upregulated the expression of vascular endothelial growth factor A (VEGF-A) in MCF-7 cells. Losartan downregulated the expression of VEGF-A in MCF-7 cells treated with angiotensin II. Candesartan downregulated the expression of VEGF-A in mice bearing MCF-7 xenografts and inhibited tumor growth and angiogenesis. AT1R and VEGF-A expression correlated with increased microvascular density in 102 breast cancer patients. Our data suggest that AT1R antagonists might be useful to suppress breast cancer by inhibiting the angiotensin II. (C) 2012 Elsevier Ireland Ltd. All rights reserved.